New Medications for Heart Failure: Ivabradine and Valsartan
This paper critiques Gordin and Fonarow's (2016) article "New Medications for Heart Failure," which examines pharmacological interventions for heart failure patients, including ACE inhibitors, beta blockers, aldosterone antagonists, and reduced ejection fraction treatments. The review focuses on two newly approved drugs — ivabradine (Corlanor) and valsartan (Entresto) — evaluating evidence from the PARADIGM-HF and SHIFT clinical trials. The paper summarizes the drugs' FDA-approved uses, proper dosages, associated side effects, and implications for nursing practice, including reduced hospitalization rates and improved patient quality of life. Strengths and limitations of the source article are also assessed.
- Overview of the Article: Purpose and scope of Gordin and Fonarow review
- Key Clinical Trials and Drug Efficacy: PARADIGM-HF and SHIFT trial findings summarized
- Dosage, Side Effects, and Treatment Planning: Drug dosages, goals, and side effect profiles
- Implications for Nursing Practice: How findings apply to clinical nursing care
- Strengths, Limitations, and Conclusion: Article critique and personal practice reflection
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper applies a structured article critique format — summarizing purpose, findings, and comparisons to related literature before evaluating strengths, weaknesses, and practice implications — making it easy to follow for a clinical audience.
- It grounds its discussion in specific named clinical trials (PARADIGM-HF and SHIFT), adding credibility and demonstrating engagement with the evidence base.
- The writer connects pharmacological findings directly to nursing practice, including concrete outcomes such as reduced readmission rates and improved quality of life, showing translational thinking.
Key academic technique demonstrated
The paper demonstrates evidence-based practice (EBP) integration: the student reads a clinical review article, cross-references it with a second source (Bas, Baser, & Nair, 2017), and then critically evaluates both the strengths and limitations of the primary article before drawing practice-relevant conclusions. This move — from literature summary to critical appraisal to practice implication — is a core skill in nursing scholarship.
Structure breakdown
The paper is organized into three functional blocks: (1) a summary of the source article's purpose and scope; (2) a comparison with a corroborating secondary source, followed by details on drug uses, dosages, and side effects; and (3) a critical appraisal section covering nursing implications, research significance, article strengths and weaknesses, and a personal reflection on how the article influenced clinical awareness. The structure mirrors standard nursing journal club or article critique assignments at the undergraduate level.
Overview of the Article
The purpose of the article by Gordin and Fonarow (2016), entitled "New Medications for Heart Failure," is to examine and discuss established guidelines for the medical treatment of heart failure. Specifically, the article examines pharmacological interventions for heart failure with regard to ACE inhibitors, beta blockers, aldosterone antagonists, and reduced ejection fraction. It reviews recent studies that have enabled new therapeutic methods to be developed using ivabradine and valsartan — the former of which decreases heart rate, and the latter of which elevates vasodilatory peptides that act as an angiotensin receptor antagonist.
The article was selected because it is timely and evaluates the "first new-in-class medications" designed to further improve quality care for patients suffering from heart failure (Gordin & Fonarow, 2016, p. 491). By examining several trials conducted for both drugs, the study demonstrates that ivabradine and valsartan are effective in decreasing hospitalizations for heart failure patients.
Key Clinical Trials and Drug Efficacy
The trials referenced in the study include the PARADIGM-HF trial and the SHIFT trial. The PARADIGM-HF trial found that valsartan helped to slow the progression of heart failure significantly better than treatment with enalapril. The SHIFT trial showed that ivabradine improved heart failure patients' quality of life, increased their ejection fraction, and reduced their end-systolic and end-diastolic volume indices.
These findings are consistent with, and compare favorably to, the conclusions of Bas, Baser, and Nair (2017), who also note the FDA's approval of both drugs and the new benefits they bring to patients suffering from heart failure, such as reduced hospitalization and improvements in quality of life.
References
Bas, H. D., Baser, K., & Nair, N. (2017). Updates on management of advanced heart failure. The Southwest Respiratory and Critical Care Chronicles, 5(20), 12–21.
Gordin, J., & Fonarow, G. (2016). New medications for heart failure. Trends in Cardiovascular Medicine, 26, 485–492.
Create your account
Always verify citation format against your institution’s current style guide requirements.